Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

Investment analysts at started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) in a report issued on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of NASDAQ:CPIX opened at $2.22 on Monday. The stock has a market capitalization of $32.55 million, a price-to-earnings ratio of -4.72 and a beta of 0.28. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.94 and a quick ratio of 1.42. The business’s fifty day moving average price is $2.42 and its two-hundred day moving average price is $2.29. Cumberland Pharmaceuticals has a fifty-two week low of $1.89 and a fifty-two week high of $7.51.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several large investors have recently bought and sold shares of the business. M Holdings Securities Inc. bought a new position in Cumberland Pharmaceuticals during the first quarter worth about $30,000. Acadian Asset Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after buying an additional 38,100 shares during the last quarter. 18.48% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

(Get Rating)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Recommended Stories

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.